The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Soft inquiry prequalifications for credit cards let you shop offers without hurting your score. This intro covers what to expect and next steps.
11,308 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Two pharma giants, two very different growth stories. This guide breaks down why Eli Lilly might be the best growth s...
Growth stocks cooled in early 2026, but a trio of ETFs offers a resilient path for long-term investors. This piece br...
Looking for steady income in a volatile market? This guide highlights three high-yield energy stocks march investors ...
A high-profile fund sold a sizable GRAIL stake right before a dramatic 50% one-day drop. This article unpacks the mov...
Lululemon faces renewed headwinds as leadership shifts and governance questions surface. This comprehensive look brea...
As the world leans harder on reliable, low-emission power, these nuclear energy stocks could offer compelling opportu...
The U.S. retirement system gets c-plus in key metrics, prompting policymakers to push overdue reforms. This report ex...
A year after GameStop added bitcoin to its treasury, the company reports a sizable impairment on digital assets amid ...
A headline like OpenAI Just Became Broadcom's New Chip Customer signals a dramatic turn in AI hardware. This article ...
Playnance's G Coin transitions from launch hype to a durability-focused utility test, as real-time staking and on-cha...
As AI headlines drive swings in tech stocks, investors ask whether Vanguard's broad tech ETF is the right pick for 20...